{"entity":{"id":"idea-gbc-national-incidental-cancer-pathway","kind":"idea","name":"A national incidental gallbladder cancer pathway: histology for every gallbladder, referral within two weeks, re-resection by eight","aka":[],"tldr":"About six in every thousand gallbladders removed for stones contain cancer. A written pathway that sends every specimen to the pathologist, refers every T1b or deeper cancer to a liver surgeon within two weeks and books the second operation within eight would turn a lottery into a system.","summary":"Incidental cancer is 0.6 percent of cholecystectomies (Pyo 2020). In the Netherlands only 24 percent of eligible patients were re-resected (2020); in the UK CAPBIL cohort 67.7 percent had liver resection (2026), with the reasons for the rest unknown. Observational data favour re-resection at four to eight weeks (Ethun 2017) though a 2026 individual patient data meta-analysis found timing did not change survival, so the pathway should prioritise completion over speed. Selective histology policies risk missing cancers (Khan 2021 systematic review). A national pathway with audit, the model the NHS uses for other two-week-wait cancers, needs no new drug and could be measured through existing registries.","asOf":"2026-09-24","links":[{"label":"de Savornin Lohman et al.: re-resection rate 24 percent in the Netherlands (Ann Surg Oncol 2020)","url":"https://europepmc.org/article/MED/31741109"},{"label":"CAPBIL: 67.7 percent liver resection across 24 UK centres (Br J Surg 2026)","url":"https://europepmc.org/article/MED/42013358"},{"label":"Khan et al.: selective versus routine histology of cholecystectomy specimens, systematic review (Asian Pac J Cancer Prev 2021)","url":"https://europepmc.org/article/MED/33773526"}],"tags":["gallbladder-evidence"],"related":[],"cancers":["gallbladder"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["incidental-gallbladder-cancer","radical-cholecystectomy"],"trials":["opt-in"],"people":[],"bottlenecks":["b-care-fragmentation","b-knowledge-diffusion"],"keyPapers":["paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020","paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020","paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026","paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017","paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A mandated pathway (routine histology, two-week referral of T1b or deeper incidental cancers to a hepatobiliary multidisciplinary team, re-resection within eight weeks where fit) will raise the proportion of eligible patients re-resected to above 80 percent and be associated with longer disease-free survival at national level.","rationale":"The intervention with the largest observed survival association in incidental gallbladder cancer is completing the radical operation; the largest documented failure is not reaching it.","test":"Stepped-wedge implementation across hepatobiliary networks with registry-linked outcomes (re-resection rate, interval, R0 rate, disease-free survival), benchmarked against the CAPBIL 2014 to 2022 baseline.","maturity":"early-clinical","actor":"clinic","cost":"small","horizonYears":4},"route":"/ideas/idea-gbc-national-incidental-cancer-pathway/","neighbours":{"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/"}],"term":[{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/"}],"trial":[{"id":"opt-in","kind":"trial","name":"OPT-IN (EA2197)","route":"/trials/opt-in/"}],"bottleneck":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/"}],"paper":[{"id":"paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017","kind":"paper","name":"Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium","route":"/key-papers/paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017/"},{"id":"paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020","kind":"paper","name":"Incidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis","route":"/key-papers/paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020/"},{"id":"paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026","kind":"paper","name":"Management of incidental gallbladder cancer in the nationwide CAPBIL study","route":"/key-papers/paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026/"},{"id":"paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020","kind":"paper","name":"Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease","route":"/key-papers/paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020/"},{"id":"paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026","kind":"paper","name":"Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis","route":"/key-papers/paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026/"}],"roadmap":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"}]}}